{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T03:55:14Z","timestamp":1765425314618,"version":"3.46.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jad.2025.120713","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T08:36:53Z","timestamp":1763627813000},"page":"120713","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"PA","title":["Real-world pharmacovigilance and clinical risks of fluvoxamine: A disproportionality analysis based on FAERS data"],"prefix":"10.1016","volume":"395","author":[{"given":"Haifeng","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiming","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenzhuang","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2025.120713_bb0005","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/S0140-6736(05)66665-2","article-title":"Depression in the elderly","volume":"365","author":"Alexopoulos","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2025.120713_bb0010","first-page":"5","article-title":"Using antipsychotic agents in older patients","volume":"65 Suppl 2","author":"Alexopoulos","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2025.120713_bb0015","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1192\/bjp.165.6.728","article-title":"Extrapyramidal symptoms with selective serotonin reuptake inhibitors","volume":"165","author":"Arya","year":"1994","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2025.120713_bb0020","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40801-014-0005-2","article-title":"Post-marketing surveillance of fluvoxamine maleate used long-term in patients with social anxiety disorder in Japan","volume":"1","author":"Asakura","year":"2014","journal-title":"Drugs Real World Outcome"},{"key":"10.1016\/j.jad.2025.120713_bb0025","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.tips.2019.07.005","article-title":"Artificial intelligence for drug toxicity and safety","volume":"40","author":"Basile","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jad.2025.120713_bb0030","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jacc.2018.06.037","article-title":"Present status of Brugada syndrome: JACC state-of-the-art review","volume":"72","author":"Brugada","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jad.2025.120713_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113301","article-title":"Mechanism, diagnosis, and treatment of cyclic Cushing\u2019s syndrome: a review","volume":"153","author":"Cai","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jad.2025.120713_bb0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/acps.13386","article-title":"Poor neonatal adaptation syndrome: toward a clinical consensus to guide research and counseling","volume":"145","author":"Carlini","year":"2022","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jad.2025.120713_bb0045","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ajp.2017.01.025","article-title":"The neurobiology of depression: an integrated view","volume":"27","author":"Dean","year":"2017","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.jad.2025.120713_bb0050","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/qjmed\/hcg109","article-title":"The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity","volume":"96","author":"Dunkley","year":"2003","journal-title":"QJM"},{"key":"10.1016\/j.jad.2025.120713_bb0055","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3390\/neurolint13030044","article-title":"Selective serotonin reuptake inhibitors and clozapine: clinically relevant interactions and considerations","volume":"13","author":"Edinoff","year":"2021","journal-title":"Neurol. Int."},{"key":"10.1016\/j.jad.2025.120713_bb0060","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1017\/S0033291712001511","article-title":"Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature","volume":"43","author":"Ferrari","year":"2013","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2025.120713_bb0065","doi-asserted-by":"crossref","first-page":"5645","DOI":"10.1017\/S0033291722002859","article-title":"Neonatal withdrawal syndrome following in utero exposure to antidepressants: a disproportionality analysis of VigiBase, the WHO spontaneous reporting database","volume":"53","author":"Gastaldon","year":"2023","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2025.120713_bb0070","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/jcbfm.1983.9","article-title":"The effects of serotonin on local cerebral blood flow","volume":"3","author":"Grome","year":"1983","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.jad.2025.120713_bb0075","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2147\/NSS.S220947","article-title":"The effect of fluvoxamine on sleep architecture of depressed patients with insomnia: an 8-week, open-label, baseline-controlled study","volume":"11","author":"Hao","year":"2019","journal-title":"Nat. Sci. Sleep"},{"key":"10.1016\/j.jad.2025.120713_bb0080","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/1389200023338017","article-title":"Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update","volume":"3","author":"Hemeryck","year":"2002","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.jad.2025.120713_bb0085","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0163-7258(99)00048-0","article-title":"Pharmacokinetics of selective serotonin reuptake inhibitors","volume":"85","author":"Hiemke","year":"2000","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jad.2025.120713_bb0090","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/NMD.0000000000001134","article-title":"A critical review of behavioral and emotional disinhibition","volume":"208","author":"Huey","year":"2020","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.jad.2025.120713_bb0095","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1038\/s41433-024-03130-0","article-title":"How should I approach and manage adult-onset oscillopsia?","volume":"38","author":"Kamath","year":"2024","journal-title":"Eye (Lond.)"},{"key":"10.1016\/j.jad.2025.120713_bb0100","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1152\/jappl.1996.80.2.680","article-title":"Brain serotonin depletion attenuates heatstroke-induced cerebral ischemia and cell death in rats","volume":"80","author":"Kao","year":"1996","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.jad.2025.120713_bb0105","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.physbeh.2007.11.037","article-title":"Neurobiology of anorexia and bulimia nervosa","volume":"94","author":"Kaye","year":"2008","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.jad.2025.120713_bb0110","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41380-022-01824-z","article-title":"Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis","volume":"28","author":"Kishi","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2025.120713_bb0115","doi-asserted-by":"crossref","first-page":"233","DOI":"10.9740\/mhc.2024.08.233","article-title":"Extrapyramidal side effects with nonantipsychotic medications","volume":"14","author":"Koch","year":"2024","journal-title":"Ment. Health Clin."},{"key":"10.1016\/j.jad.2025.120713_bb0120","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00019052-199408000-00013","article-title":"Neuroleptic malignant syndrome","volume":"7","author":"Kornhuber","year":"1994","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.jad.2025.120713_bb0125","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.therap.2022.10.002","article-title":"Sex differences in adverse drug reactions: are women more impacted?","volume":"78","author":"Lacroix","year":"2023","journal-title":"Therapie"},{"key":"10.1016\/j.jad.2025.120713_bb0130","doi-asserted-by":"crossref","DOI":"10.2196\/46538","article-title":"Challenges and implications for menopausal health and help-seeking behaviors in midlife women from the United States and China in light of the COVID-19 pandemic: web-based panel surveys","volume":"10","author":"Lau","year":"2024","journal-title":"JMIR Public Health Surveill."},{"key":"10.1016\/j.jad.2025.120713_bb0135","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1186\/s12889-024-19077-6","article-title":"YouTube\/Bilibili\/TikTok videos as sources of medical information on laryngeal carcinoma: cross-sectional content analysis study","volume":"24","author":"Liu","year":"2024","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jad.2025.120713_bb0140","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s00210-002-0567-5","article-title":"Block of volume-regulated anion channels by selective serotonin reuptake inhibitors","volume":"366","author":"Maertens","year":"2002","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.jad.2025.120713_bb0145","first-page":"323","article-title":"A review of neonatal selective serotonin reuptake inhibitor withdrawal syndrome","volume":"30","author":"Mamillapalli","year":"2025","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"10.1016\/j.jad.2025.120713_bb0150","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.2174\/092986712800099749","article-title":"Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions","volume":"19","author":"Mandrioli","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jad.2025.120713_bb0155","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1176\/ajp.149.3.413","article-title":"Fluoxetine and fluvoxamine in PTSD","volume":"149","author":"March","year":"1992","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2025.120713_bb0160","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1176\/appi.ajp.162.4.812","article-title":"Neuroleptic malignant syndrome induced by quetiapine and fluvoxamine","volume":"162","author":"Matsumoto","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2025.120713_bb0165","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.placenta.2017.08.010","article-title":"Quantitative prediction of fetal plasma concentration of fluvoxamine during dosage-tapering to the mother","volume":"58","author":"Matsuoka","year":"2017","journal-title":"Placenta"},{"key":"10.1016\/j.jad.2025.120713_bb0170","doi-asserted-by":"crossref","first-page":"101","DOI":"10.17116\/jnevro2024124061101","article-title":"[Fluvoxamine in the treatment of anxiety-depressive spectrum disorders]","volume":"124","author":"Medvedev","year":"2024","journal-title":"Zh. Nevrol. Psikhiatr. Im. S.S. Korsakova"},{"key":"10.1016\/j.jad.2025.120713_bb0175","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2165\/00003495-199200432-00006","article-title":"Efficacy of fluvoxamine in severe depression","volume":"43 Suppl 2","author":"Mendlewicz","year":"1992","journal-title":"Drugs"},{"key":"10.1016\/j.jad.2025.120713_bb0180","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1017\/S109285292000214X","article-title":"Use of selective serotonin and norepinephrine reuptake inhibitors (SNRIs) in the treatment of autism spectrum disorder (ASD), comorbid psychiatric disorders and ASD-associated symptoms: a clinical review","volume":"27","author":"Nanjappa","year":"2022","journal-title":"CNS Spectr."},{"key":"10.1016\/j.jad.2025.120713_bb0185","article-title":"Fluvoxamine for the treatment of COVID-19","volume":"9","author":"Nyirenda","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jad.2025.120713_bb0190","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.lfs.2012.11.005","article-title":"Chronic fluvoxamine treatment changes 5-HT(2A\/2C) receptor-mediated behavior in olfactory bulbectomized mice","volume":"92","author":"Oba","year":"2013","journal-title":"Life Sci."},{"key":"10.1016\/j.jad.2025.120713_bb0195","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/MAJ.0000000000000341","article-title":"Cardiac vasoplegia syndrome: pathophysiology, risk factors and treatment","volume":"349","author":"Omar","year":"2015","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.jad.2025.120713_bb0200","article-title":"Fluvoxamine versus other anti-depressive agents for depression","volume":"2010","author":"Omori","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jad.2025.120713_bb0205","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s12888-020-02711-z","article-title":"Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database","volume":"20","author":"Revet","year":"2020","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jad.2025.120713_bb0210","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/sj.npp.1300003","article-title":"Fluvoxamine reduces responsiveness of HPA axis in adult female BPD patients with a history of sustained childhood abuse","volume":"28","author":"Rinne","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2025.120713_bb0215","doi-asserted-by":"crossref","first-page":"712","DOI":"10.4103\/ijo.IJO_833_17","article-title":"Fluvoxamine-induced intracranial hypertension in a 10-year-old boy","volume":"66","author":"Samant","year":"2018","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.jad.2025.120713_bb0220","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1001\/archgenpsychiatry.2010.39","article-title":"Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years\u2019 data","volume":"67","author":"Schneeweiss","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2025.120713_bb0225","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1515\/dmpt-2015-0006","article-title":"Fluvoxamine-associated oscillopsia and a role for personalized medication dosing","volume":"30","author":"Singman","year":"2015","journal-title":"Drug Metab. Pers. Ther."},{"key":"10.1016\/j.jad.2025.120713_bb0230","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.652688","article-title":"Fluvoxamine: a review of its mechanism of action and its role in COVID-19","volume":"12","author":"Sukhatme","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jad.2025.120713_bb0235","doi-asserted-by":"crossref","first-page":"H1535","DOI":"10.1152\/ajpheart.00198.2010","article-title":"Sigma1-receptor stimulation with fluvoxamine ameliorates transverse aortic constriction-induced myocardial hypertrophy and dysfunction in mice","volume":"299","author":"Tagashira","year":"2010","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.jad.2025.120713_bb0240","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/WCO.0b013e328341e3b5","article-title":"Oscillopsia: causes and management","volume":"24","author":"Tilikete","year":"2011","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.jad.2025.120713_bb0245","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4103\/ipj.ipj_146_20","article-title":"A study to understand the pattern of hyponatremia in patients using selective serotonin reuptake inhibitors and serotonin dopamine antagonists","volume":"30","author":"Tomar","year":"2021","journal-title":"Ind. Psychiatry J."},{"issue":"Suppl. 1","key":"10.1016\/j.jad.2025.120713_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199500291-00003","article-title":"Overview of the pharmacokinetics of fluvoxamine","volume":"29","author":"van Harten","year":"1995","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jad.2025.120713_bb0255","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.jad.2025.120713_bb0260","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.schres.2023.10.003","article-title":"Optimizing antidepressant and clozapine co-prescription in clinical practice: a systematic review and expert recommendations","volume":"268","author":"Verdoux","year":"2024","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jad.2025.120713_bb0265","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s002280050729","article-title":"Fluvoxamine but not citalopram increases serum melatonin in healthy subjects\u2014an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin","volume":"56","author":"von Bahr","year":"2000","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jad.2025.120713_bb0270","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1186\/s12877-024-05371-w","article-title":"Serotonin syndrome caused by escitalopram in Parkinson\u2019s disease psychosis: a case report","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Geriatr."},{"key":"10.1016\/j.jad.2025.120713_bb0275","doi-asserted-by":"crossref","first-page":"895","DOI":"10.2165\/00003495-199346050-00008","article-title":"Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness","volume":"46","author":"Wilde","year":"1993","journal-title":"Drugs"},{"key":"10.1016\/j.jad.2025.120713_bb0280","article-title":"Serotonin syndrome caused by a CYP2C19-mediated interaction between low-dose escitalopram and clopidogrel: a case report","volume":"14","author":"Wu","year":"2023","journal-title":"Front. Psych."},{"key":"10.1016\/j.jad.2025.120713_bb0285","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12991-024-00513-1","article-title":"Global, regional, and national time trends in incidence for depressive disorders, from 1990 to 2019: an age-period-cohort analysis for the GBD 2019","volume":"23","author":"Wu","year":"2024","journal-title":"Ann. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2025.120713_bb0290","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.survophthal.2021.11.007","article-title":"Papilledema: a review of etiology, pathophysiology, diagnosis, and management","volume":"67","author":"Xie","year":"2022","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.jad.2025.120713_bb0295","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0022-3565(25)22061-4","article-title":"Dopaminergic and serotonergic mechanisms of thermoregulation: mediation of thermal effects of apomorphine and dopamine","volume":"227","author":"Yamawaki","year":"1983","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jad.2025.120713_bb0300","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA Adverse Event Reporting System (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016503272502155X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016503272502155X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T03:50:12Z","timestamp":1765425012000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016503272502155X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":60,"alternative-id":["S016503272502155X"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2025.120713","relation":{},"ISSN":["0165-0327"],"issn-type":[{"type":"print","value":"0165-0327"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world pharmacovigilance and clinical risks of fluvoxamine: A disproportionality analysis based on FAERS data","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2025.120713","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120713"}}